



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 72

(48) Corrigendum issued on:
11.12.2019 Bulletin 2019/50

(45) Date of publication and mention
of the grant of the patent:
09.05.2018 Bulletin 2018/19

(21) Application number: **14713401.9**

(22) Date of filing: **14.03.2014**

(51) Int Cl.:
C07K 14/495^(2006.01) C12N 15/113^(2010.01)
A61K 48/00^(2006.01)

(86) International application number:
PCT/EP2014/055195

(87) International publication number:
WO 2014/140333 (18.09.2014 Gazette 2014/38)

(54) **METHODS OF TREATING COLORECTAL CANCER**

VERFAHREN ZUR BEHANDLUNG VON KOLOREKTALKREBS

MÉTHODES DE TRAITEMENT DU CANCER COLORECTAL

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: **15.03.2013 US 201361790488 P**
17.07.2013 US 201361847287 P

(43) Date of publication of application:
20.01.2016 Bulletin 2016/03

(73) Proprietor: **Nogra Pharma Limited**
Dublin 2 (IE)

(72) Inventors:
• **MONTELEONE, Giovanni**
Grottaferrata 00046 (Roma) (IT)
• **BELLINVIA, Salvatore**
6850 Mendrisio (CH)
• **VITI, Francesca**
6872 Salorino (CH)

(74) Representative: **Tomkins & Co**
5 Dartmouth Road
Dublin 6 (IE)

(56) References cited:
WO-A1-2004/087920 WO-A1-2010/063472
WO-A1-2013/037970

- **LI QIANG ET AL: "MicroRNA-25 functions as a potential tumor suppressor in colon cancer by targeting Smad7", CANCER LETTERS, NEW YORK, NY, US, vol. 335, no. 1, 19 February 2013 (2013-02-19), pages 168-174, XP028551326, ISSN: 0304-3835, DOI: 10.1016/J.CANLET.2013.02.029**
- **S K HALDER ET AL: "Smad7 induces hepatic metastasis in colorectal cancer", BRITISH JOURNAL OF CANCER, vol. 99, no. 6, 19 August 2008 (2008-08-19), pages 957-965, XP055120588, ISSN: 0007-0920, DOI: 10.1038/sj.bjc.6604562**
- **BOULAY JEAN-LOUIS ET AL: "Combined copy status of 18q21 genes in colorectal cancer shows frequent retention of SMAD7", GENES CHROMOSOMES & CANCER, JOHN WILEY & SONS, INC, US, vol. 31, no. 3, 1 July 2001 (2001-07-01), pages 240-247, XP002516294, ISSN: 1045-2257, DOI: 10.1002/GCC.1140**
- **RIZZO ANGELAMARIA ET AL: "Smad7 expression in T cells prevents colitis-associated cancer.", CANCER RESEARCH 15 DEC 2011, vol. 71, no. 24, 15 December 2011 (2011-12-15), pages 7423-7432, XP002725216, ISSN: 1538-7445**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- | | |
|--|--|
| <ul style="list-style-type: none">• C STOLFI ET AL: "A functional role for Smad7 in sustaining colon cancer cell growth and survival", CELL DEATH AND DISEASE, vol. 5, no. 2, 20 February 2014 (2014-02-20), page e1073, XP055120595, DOI: 10.1038/cddis.2014.49 | <ul style="list-style-type: none">• LI QIANG ET AL: "MicroRNA-25 functions as a potential tumor suppressor in colon cancer by targeting Smad7", CANCER LETTERS, vol. 335, no. 1, 19 February 2013 (2013-02-19), pages 1-2, |
|--|--|